Beyond Aerobic Fitness: Effects of Coordination and Aerobic Exercise on Executive Functions in School-Aged Children

June 13, 2026 updated by: Görkem Açar, Istanbul Gelisim University

Beyond Aerobic Fitness: A Randomized Controlled Trial Comparing the Effects of Coordination and Aerobic Exercise on Executive Functions in School-Aged Children

This randomized controlled trial aims to compare the effects of aerobic exercise and coordination-based exercise on executive functions in school-aged children aged 10 to 12 years. Executive functions, including working memory and selective attention, are essential cognitive skills that support learning, academic achievement, problem-solving, and daily functioning.

A total of 78 healthy children will be randomly assigned to one of three groups: an Aerobic Exercise Group, a Coordination Exercise Group, or a Control Group. Participants in the intervention groups will complete supervised exercise sessions lasting 40 minutes, three times per week, for 14 weeks. The aerobic exercise program will include activities designed to improve cardiovascular fitness, while the coordination exercise program will involve tasks requiring motor control, balance, bilateral coordination, and cognitive engagement. Participants in the control group will continue their usual school activities without additional structured exercise.

Working memory and selective attention will be assessed before and after the intervention using standardized neuropsychological tests. The findings of this study may improve understanding of how different types of physical activity influence cognitive development in children and may help educators and health professionals design more effective school-based physical activity programs that support both physical and cognitive health.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
78

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey (Türkiye)
    • Istanbul
      • Istanbul, Istanbul, Turkey (Türkiye), 34570
        • Istanbul Rumeli University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Children aged between 10 and 12 years.
  • Typically developing children without diagnosed neurological, developmental, or physical disorders.
  • Written informed consent obtained from parents or legal guardians.
  • Child assent provided before participation.

Exclusion Criteria:

  • Diagnosis of attention-deficit/hyperactivity disorder (ADHD).
  • Presence of learning disabilities.
  • Neurological, developmental, or chronic medical conditions limiting participation in physical activity.
  • Attendance of less than 80% of the intervention sessions.
  • Occurrence of health problems during the study period that prevented continued participation.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Aerobic Exercise Group
Participants completed a supervised aerobic exercise program for 14 weeks, consisting of 40-minute sessions conducted three times per week. The program included high-intensity interval activities, sprint running, and game-based aerobic exercises designed to improve cardiorespiratory fitness.
Behavioral: Aerobic Exercise Program
Participants completed a supervised aerobic exercise program for 14 weeks. Exercise sessions were conducted three times per week and lasted 40 minutes each. The intervention included high-intensity interval activities, sprint running, and game-based aerobic tasks designed to improve cardiorespiratory fitness. Exercise intensity was monitored using heart rate monitors, and participants maintained an intensity corresponding to 65% to 85% of their age-predicted maximum heart rate.
Other Names:
  • Aerobic Training
Experimental: Coordination Exercise Group
Participants completed a supervised coordination-based exercise program for 14 weeks, consisting of 40-minute sessions conducted three times per week. Activities included jump-rope combinations, dynamic balance exercises, bilateral coordination tasks, and multidirectional movement tasks requiring cognitive engagement.
Behavioral: Coordination Exercise Program
Participants completed a supervised coordination-based exercise program for 14 weeks. Exercise sessions were conducted three times per week and lasted 40 minutes each. The intervention included jump-rope combinations, dynamic balance exercises, bilateral coordination activities, and multidirectional movement tasks requiring cognitive engagement. Exercise intensity was standardized using ratings of perceived exertion, targeting Borg scale scores between 13 and 16.
Other Names:
  • Coordination Training
No Intervention: Control Group
Participants continued their usual school curriculum and daily activities without receiving any additional structured exercise intervention during the study period.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Working Memory
Time Frame: Baseline and Week 14
Working memory performance will be assessed using the Visual-Auditory Digit Span Test. The test evaluates the ability to temporarily store, manipulate, and recall information through auditory and visual modalities. Higher scores indicate better working memory performance.
Baseline and Week 14
Selective Attention
Time Frame: Baseline and Week 14
Selective attention will be assessed using the d2 Test of Attention. Outcome measures include concentration performance, processing speed, and error rates. Higher concentration scores indicate better selective attention performance.
Baseline and Week 14

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Motor Coordination
Time Frame: Baseline
Motor coordination will be evaluated using the Körperkoordinationstest für Kinder (KTK) test battery. The assessment includes balance, jumping, and movement coordination tasks, with scores converted into an overall Motor Quotient.
Baseline
Cardiorespiratory Fitness
Time Frame: Baseline
Cardiorespiratory fitness will be assessed using the 20-meter shuttle run test. Maximal oxygen uptake (VO₂max) will be estimated from test performance.
Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Istanbul Gelisim University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
March 1, 2026

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
June 10, 2026

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
June 10, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
June 13, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 13, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
June 22, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
June 22, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 13, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
June 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • IRU-2026-02-08

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Working Memory

Clinical Trials on Aerobic Exercise Program

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings